In a significant move, French health officials have extended the country’s experimental medical cannabis program for an additional six months, as reported by RFI. Initially set to expire on December 31, 2024, the program will now continue until July 31, 2025. This extension aims to provide patients with extra time to taper their cannabis consumption or explore alternative treatments.

Background of the Medical Cannabis Program

The pilot program for medical cannabis was launched in March 2021, enrolling around 3,000 patients suffering from chronic ailments. Participating healthcare professionals are experts in various fields, including pain management, oncology, neurology, epilepsy, multiple sclerosis, and palliative care. Its primary objective is to investigate the effects of medical cannabis and its derivatives on these patients.

Current Legal Status of Cannabis in France

While the medical cannabis program provides limited legal access to medicinal cannabis, the broader use of cannabis remains strictly prohibited across France. However, in recent years, there has been a notable increase in shops selling low-THC, CBD-rich hemp products. In December 2021, the French government attempted to ban the possession, use, and sale of CBD products. Nonetheless, a ruling by the Constitutional Council a month later overturned this ban, asserting that CBD is neither addictive nor harmful.

Government’s Stance on Adult-Use Cannabis

Recently appointed French Health Minister, Yannick Neuder, expressed support for ongoing research into medical cannabis. However, he remains firmly opposed to the legalization of cannabis for recreational use. In 2020, a collective of French MPs similarly voiced their objections to efforts aimed at legalizing adult-use cannabis in the country.

Ongoing Discussions and Future Implications

The extension of the medical cannabis program allows for further exploration into how cannabis can effectively assist patients with chronic conditions. It raises several important questions about the future of cannabis regulation in France. While the medical program is an important step, the ongoing debates around adult-use legalization highlight the complexities of cannabis policies in the country.

In conclusion, as the medical cannabis program undergoes evaluation and continuation, it is essential for stakeholders, including health officials and patients, to engage in discussions about both the potential benefits and risks of cannabis consumption. Moreover, this extension provides crucial data that could inform future policy decisions regarding cannabis use in France.

Get daily cannabis business news updates. Subscribe

• Canada
• CO
• WA
• OR
• NV
• DC
• TX
• NY
• FL

• Stocks
• CBD
• Legalization
• Decriminalization
• Business

Frequently Asked Questions